上皮性卵巢癌新辅助化疗与初次肿瘤细胞减灭术后的总生存:美国国家癌症数据库分析
基于美国国家癌症数据库2003至2011年诊断的IIIC和IV期上皮性卵巢癌女性,回顾性比较初次肿瘤细胞减灭术(PCS)与新辅助化疗(NACT)的总生存。在倾向性评分匹配队列中,PCS组中位总生存37.3个月,NACT组32.1个月(P<.001);但若NACT组体能状态1-2比例更高(60% vs 50%),PCS与生存改善的关联将无统计学显著性。
要点
- 匹配队列中PCS组中位总生存37.3个月 vs NACT组32.1个月(P<.001)。
- 若NACT组体能状态1-2比例更高(60% vs 50%),PCS生存优势无统计学显著性。
- NACT组生存较低可能由体能状态受限比例更高解释。
核心结论
- 在70岁及以下、Charlson合并症指数为0的晚期上皮性卵巢癌女性中,初次肿瘤细胞减灭术与较新辅助化疗改善的生存相关。
- 接受新辅助化疗的女性生存较低,可能由该组体能状态受限比例更高解释。
研究设计与样本
- 回顾性队列研究,纳入美国国家癌症数据库2003至2011年诊断的IIIC和IV期上皮性卵巢癌女性。
- 聚焦70岁及以下、Charlson合并症指数为0、可能适合任一治疗的患者。
- 共22962例患者,平均(SD)年龄56.12(9.38)岁;19836例(86.4%)接受PCS,3126例(13.6%)接受NACT。
- 采用意向性治疗分析,并以倾向性评分匹配比较相似女性。
主要发现
- 匹配2935例NACT患者与相似PCS患者;匹配队列中PCS组中位随访56.5个月(95%CI 54.5-59.2),NACT组56.3个月(95%CI 54.5-59.8)。
- 倾向性评分匹配组中,PCS组中位总生存37.3个月(95%CI 35.2-38.7),NACT组32.1个月(95%CI 30.8-34.1)(P<.001)。
- 若NACT组体能状态1-2比例高于PCS组(60% vs 50%),PCS与生存改善的关联将无统计学显著性。
局限性
- 原文提及未观测混杂因素(如体能状态受限、术前疾病负荷和BRCA状态)可能影响结果。
- 原文指出若NACT组体能状态1-2比例更高(60% vs 50%),PCS与生存改善的关联将无统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Uncertainty remains about the relative benefits of primary cytoreductive surgery (PCS) vs neoadjuvant chemotherapy (NACT) for advanced-stage epithelial ovarian cancer (EOC). OBJECTIVE: To compare overall survival of PCS vs NACT in a large national population of women with advanced-stage EOC. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of women with stage IIIC and IV EOC diagnosed between 2003 and 2011 treated at hospitals across the United States reporting to the National Cancer Data Base. We focused on patients 70 years or younger with a Charlson comorbidity index of 0 who were likely candidates for either treatment. EXPOSURES: Initial treatment approach of PCS vs NACT, examined using an intent-to-treat analysis. MAIN OUTCOMES AND MEASURES: Overall survival, defined as months from cancer diagnosis to death or date of the last contact. We used propensity score matching to compare similar women who underwent PCS and NACT. The association of treatment approach with overall survival was assessed using the Kaplan-Meier method and the log-rank test. We assessed whether the findings were influenced by differences in the prevalence of an unobserved confounder, such as limited performance status (Eastern Cooperative Oncology Group 1-2), preoperative disease burden, and BRCA status. RESULTS: Among 22 962 patients (mean [SD] age, 56.12 [9.38] years), 19 836 (86.4%) received PCS and 3126 (13.6%) underwent NACT. We matched 2935 patients treated with NACT with similar patients who received PCS. The median follow-up was 56.5 (95% CI, 54.5-59.2) months in the PCS group and 56.3 (95% CI, 54.5-59.8) months in the NACT group in the propensity-matched cohort. Among propensity score-matched groups, the median overall survival was 37.3 (95% CI, 35.2-38.7) months in the PCS group and 32.1 (95% CI, 30.8-34.1) months in the NACT group (P < .001). However, if the NACT group had a higher proportion of women with performance statuses of 1 to 2 compared with those who underwent PCS (60% vs 50%), the association of PCS and improved survival would not be statistically significant. CONCLUSIONS AND RELEVANCE: Primary cytoreductive surgery was associated with improved survival compared with NACT in otherwise healthy women with advanced-stage epithelial ovarian cancer aged 70 years or younger. The lower survival in women who received NACT could be explained by a higher prevalence of limited performance status in women undergoing NACT.
引用
- Rauh-Hain JA, Melamed A, Wright A, et al. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database. JAMA Oncol. 2017. PMID: 27892998. doi:10.1001/jamaoncol.2016.4411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。